Strong of its results after years of research, STEMAXON provides a new platform (patent pending) for the pharmaceutical industry to test their lead compounds against Alzheimer’ disease.
This unique platform greatly increase the efficiency to validate existing molecules for drug development and treatment. Currently, pharmaceutical companies can require up to 5 years to validate a single molecule. Using this platform, the same results can be completed in less than 6 months and at a fraction of the cost.
Pre-clinical validation of lead compounds against sporadic Alzheimer’ disease using disease-modeling human neurons
Cell biology: We can validate the compound efficiency by analyzing up to 7 different disease parameters, including amyloid-beta secretion and accumulation, p-Tau accumulation, cell death, synaptic atrophy, etc.
Molecular biology: We can provide the complete differential RNA-seq analysis of the compound(s) effect on treated and untreated control and Alzheimer's disease neurons.
Toxicity: We can provide toxicity analyses of the compound effect on human embryonic stem cells, human induced pluripotent stem cells, embryoid bodies and differentiated neurons.
Medium to large throughput screen for the isolation and development of new drugs against sporadic Alzheimer's disease
STEMAXON is developing a reporter system enabling large throughput drug screening in human neurons.
STEMAXON is launching its own R&D program to isolate and develop novel drugs against sporadic Alzheimer's disease.
Test your compounds on our unique sporadic Alzheimer's disease models
Sporadic Alzheimer’s disease (AD) is the most common dementia with an estimated prevalence of 5.2 million Americans in 2014 (Hebert et al., 2013). Total payments in 2014 for all individuals with AD and other dementias are estimated at $214 billion in the US (American Alzheimer’s Association 2014 report).
Despite numerous clinical trials, there are actually no treatments to stop or delay AD (De Strooper and Chavez Gutierrez, 2014). The brain changes in AD begin 20 or more years before symptoms appear (Villemagne et al., 2013). 11% of people aged 65 and older have AD. 32% of people aged 85 and older have AD. The greatest risk factor to develop AD is advanced age (Savva et al., 2009).
Furthermore, carriers of the E4 allele of APOLIPOPROTEIN have increased risk to develop AD (Kanekiyo et al., 2014). In contrast, familial AD (FAD) is an autosomal dominant genetic disease that occurs between the ages of 30-50 year and linked to mutation in APP, PSEN1 or PSEN2 (Blennow et al., 2006). AD and FAD are both characterized by progressive memory and behavioral impairment owing to degeneration of limbic and cortical areas of the brain. Pathological hallmarks of the disease are the presence of amyloid plaques, neurofibrillary phospho-Tau tangles and synaptic dysfunction (Blennow et al., 2006). Notably, the etiology of AD remains elusive.
While amyloid brain accumulation is the common hallmark of AD, why amyloid metabolism is perturbed is unknown. Whether amyloid-independent pathologies also operate in disease initiation and/or progression is also an open question.
It could be stated that the main reason of this immense knowledge-gap is the lack of experimental models of AD for which the disease origin is known. This knowledge-gap is also the reason for the successive failure of the pharmaceutical industry to develop efficient AD therapeutics.
Blennow, K., de Leon, M.J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403.
De Strooper, B., and Chavez Gutierrez, L. (2014). Learning by Failing: Ideas and Concepts to Tackle gamma-Secretases in Alzheimer's Disease and Beyond. Annu Rev Pharmacol Toxicol 55, 419-437.
Hebert, L.E., Weuve, J., Scherr, P.A., and Evans, D.A. (2013). Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778-1783.
Kanekiyo, T., Xu, H., and Bu, G. (2014). ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron 81, 740-754.
Savva, G.M., Wharton, S.B., Ince, P.G., Forster, G., Matthews, F.E., and Brayne, C. (2009). Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C.,
Macaulay, S.L., Martins, R., Maruff, P., et al. (2013). Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12, 357-367.